Henry Schein Stock: The Upside Isn't Over (NASDAQ:HSIC)

Henry Schein's (NASDAQ:HSIC) profitability metrics present a mixed picture. Adjusted net income and EBITDA are trending higher. That combination supports the buy thesis laid out by Crude Value Insights.

The healthcare distributor, with a market cap of roughly $10 billion, has seen its adjusted earnings and cash flow measures improve in recent quarters. Some profitability ratios lagged. Core earnings measures that strip out one-time items improved.

For investors weighing a position, the rising adjusted net income and EBITDA provide a foundation for the stock's current valuation. The analysis from Crude Value Insights concludes that Henry Schein is a Buy.

Find the analysis on our stock market analysis page.